RxDoctor Payments Data

Kelsey Temple, MD

Family Medicine · New Kensington, PANPI 1255952818

Payments from drug & device makers

$1,511in general payments, 2019–2025

Across 68 payments — averaging $22.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$580
  • AstraZeneca$273
  • Exact Sciences$206
  • Vivus LLC$120
  • Shield Therapeutics Inc$76
  • Amgen$58
  • plus $199 from 7 others

What the payments were for

  • Food & beverage$1,511100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,511 in reported general payments places this provider in the 70th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$58,708
Medicare patients
152
Services billed
867

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban47$56,631
FarxigaDapagliflozin Propanediol46$38,258
JardianceEmpagliflozin29$35,463
OzempicSemaglutide16$31,989
JanuviaSitagliptin Phosphate21$23,016
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$22,843
MounjaroTirzepatide18$22,114
XareltoRivaroxaban11$14,708
Breo ElliptaFluticasone/Vilanterol13$8,739
Varenicline Tartrate17$7,601
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$6,656
Atorvastatin Calcium339$4,749
Albuterol Sulfate HfaAlbuterol Sulfate119$3,390
Rosuvastatin Calcium127$2,765
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$2,074

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14$56,63147 claims
AstraZenecaFarxiga$273$38,25846 claims
Novo NordiskOzempic$580$31,98916 claims
MerckJanuvia$14$23,01621 claims
Lilly USA, LLCMounjaro$47$22,11418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in New Kensington

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →